House splits on medical‑cannabis testing and track‑and‑trace; several committee reports defeated
Loading...
Summary
Lawmakers engaged in a long, sometimes contentious debate over LD 1847 and related measures to require testing and tracking for medical cannabis. Multiple committee reports and amendments failed on the floor (report a: 43–102; report c: 71–74), and opponents warned of steep costs for small caregivers while supporters cited patient safety.
The House spent much of the day debating LD 1847 and associated committee reports and amendments that would require mandatory product testing, laboratory certification, and a track‑and‑trace system for medical cannabis. Lawmakers deliberated competing priorities: patient safety and contamination testing versus the costs and administrative burdens on small caregivers and outdoor growers.
Supporters of the mandatory testing framework argued it protects medically vulnerable patients. Representative Zaker (Portland) framed the issue in clinical terms, invoking the medical maxim in floor remarks: "Primum non nascare, which is first do no harm," and urged colleagues to adopt testing and tracking to prevent toxic products from reaching patients. Proponents cited studies and anecdotal incidents showing contaminants in some products and called for parity between medical and adult‑use testing standards.
Opponents warned that the proposed system would be cost‑prohibitive for many small caregivers and growers and could push consumers toward the illicit market. Representative Boyer warned the measure would "put hundreds of small caregivers out of business" and criticized mandatory adoption of a single track‑and‑trace software (Metrc), calling the approach ill‑suited for small-scale and outdoor cultivators. Representative Fredericks described costs and monthly burdens that could be passed to patients and small operators.
The House voted on competing committee reports and amendments. The clerk read results on the floor: one committee report (report a) was defeated by a roll call of 43–102, and a separate committee report (report c) failed 71–74. Later the House recorded a motion that report d "ought not to pass" and the matter was sent forward per the clerk’s announcement. Floor debate also included multiple spoke‑for and spoke‑against exchanges, with public‑health groups, law‑enforcement, and industry stakeholders referenced by members.
The transcript records substantial disagreement about whether mandatory testing would reduce public‑health risks or mainly raise costs and consolidate market share among larger firms. Lawmakers noted options for audit testing and department enforcement as alternative paths. The floor record does not show a final enacted statutory change on this bill in the House transcript; the measures and committee recommendations were moved and remanded according to floor procedure.